PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells

Cancer Biology and Therapy

Volumn 14, Issue 5, 2013, Pages 458-465

  Booth, Laurence ^a   Cruickshanks, Nichola ^a   Ridder, Thomas ^a   Dai, Yun ^a   Grant, Steven ^a   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; ATM; CHK1; Comet; DNA damage; Kinase; PARP1

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; 7 HYDROXYSTAUROSPORINE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; CHECKPOINT KINASE 1 INHIBITOR; HISTONE H2AX; MITOGEN ACTIVATED PROTEIN KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHOSPHOTRANSFERASE INHIBITOR; RABUSERTIB; RUCAPARIB; UNCLASSIFIED DRUG; VELIPARIB;

ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SINGLE STRANDED DNA BREAK; TUMOR CELL DESTRUCTION;

APOPTOSIS; ATM; CHK1; COMET; DNA DAMAGE; KINASE; PARP1;

APOPTOSIS; BREAST NEOPLASMS; CELL DEATH; DNA DAMAGE; FEMALE; HISTONES; HUMANS; MAP KINASE KINASE 1; MCF-7 CELLS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84877857730     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.24424     Document Type: Article

References (41)

1. Lukas C, Falck J, Bartkova J, Bartek J, Lukas J. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol 2003; 5:255-60; PMID:12598907; http://dx.doi.org/10.1038/ncb945.
2. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. H2AX: the histone guardian of the genome. DNA Repair (Amst) 2004; 3:959-67; PMID:15279782; http://dx.doi.org/10.1016/j.dnarep.2004.03.024.
3. Lee JH, Paull TT. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 2007; 26:7741-8; PMID:18066086; http://dx.doi.org/10.1038/sj.onc.1210872.
4. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3:421-9; PMID:12781359; http://dx.doi.org/10.1016/ S1535-6108(03)00110-7.
5. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70:4972-81; PMID:20501833; http://dx.doi.org/10.1158/ 0008-5472.CAN-09-3573.
6. Mow BM, Blajeski AL, Chandra J, Kaufmann SH. Apoptosis and the response to anticancer therapy. Curr Opin Oncol 2001; 13:453-62; PMID:11673685; http://dx.doi.org/10.1097/00001622-200111000-00007.
7. Prudhomme M. Novel checkpoint 1 inhibitors. Recent Pat Anticancer Drug Discov 2006; 1:55-68; PMID:18221026; http://dx.doi.org/10.2174/ 157489206775246520.
8. Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R, et al. Pharmacological inhibitors of the mitogen-Activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 2001; 61:5106-15; PMID:11431348.
9. Dai Y, Landowski TH, Rosen ST, Dent P, Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 2002; 100:3333-43; PMID:12384435; http://dx.doi.org/10.1182/ blood-2002-03-0940.
10. Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitorinduced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 2008; 112:2439-49; PMID:18614762; http://dx.doi.org/10.1182/blood-2008-05-159392.
11. Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, et al. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Mol Cancer Ther 2008; 7:616-29; PMID:18347148; http://dx.doi.org/10.1158/1535-7163.MCT-07-2376.
12. Mitchell C, Park M, Eulitt P, Yang C, Yacoub A, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells. Mol Pharmacol 2010; 78:909-17; PMID:20696794; http://dx.doi.org/10.1124/mol.110. 067199.
13. Tang Y, Hamed HA, Poklepovic A, Dai Y, Grant S, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Mol Pharmacol 2012; 82:322-32; PMID:22596349; http://dx.doi.org/10.1124/mol.112. 078907.
14. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14:1351-6; PMID:19029981; http://dx.doi.org/10.1038/nm.1890.
15. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10:293-301; PMID:20200537; http://dx.doi.org/10.1038/nrc2812.
16. Amé JC, Rolli V, Schreiber V, Niedergang C, Apiou F, Decker P, et al. PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 1999; 274:17860-8; PMID:10364231; http://dx.doi.org/10.1074/jbc.274. 25.17860.
17. Schreiber V, Amé JC, Dollé P, Schultz I, Rinaldi B, Fraulob V, et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002; 277:23028-36; PMID:11948190; http://dx.doi.org/10.1074/jbc.M202390200.
18. Graziani G, Szabó C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005; 52:109-18; PMID:15911339; http://dx.doi.org/10.1016/j.phrs. 2005.02.013.
19. Arundel-Suto CM, Scavone SV, Turner WR, Suto MJ, Sebolt-Leopold JS. Effect of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells. Radiat Res 1991; 126:367-71; PMID:1903547; http://dx.doi.org/10.2307/3577927.
20. Ben-Hur E, Chen CC, Elkind MM. Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. Cancer Res 1985; 45:2123-7; PMID:2985245.
21. Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 1995; 72:849-56; PMID:7547230; http://dx.doi.org/10.1038/bjc.1995.423.
22. Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 2001; 84:106-12; PMID:11139322; http://dx.doi.org/10.1054/bjoc.2000.1555.
23. Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 1998; 78:1269-77; PMID:9823965; http://dx.doi.org/10.1038/bjc.1998.670.
24. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000; 6:2860-7; PMID:10914735.
25. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002; 45:73-85; PMID:11846617; http://dx.doi.org/10.1006/phrs.2001.0935.
26. Rodon J, Iniesta MD, Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opin Investig Drugs 2009; 18:31-43; PMID:19053880; http://dx.doi.org/10.1517/13543780802525324.
27. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNAdamaging agents in preclinical tumor models. Clin Cancer Res 2007; 13:2728-37; PMID:17473206; http://dx.doi.org/10.1158/1078-0432.CCR-06-3039.
28. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66:11954-66; PMID:17178894; http://dx.doi.org/10. 1158/0008-5472.CAN-06-1666.
29. Weiss GJ, Donehower RC, Iyengar T, Ramanathan RK, Lewandowski K, Westin E, et al. Phase I doseescalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs 2013; 31:136-44; PMID:22492020; http://dx.doi.org/10.1007/s10637-012-9815-9.
30. Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv 2011; 11:133-40; PMID:21540473; http://dx.doi.org/10.1124/mi.11.2.11.
31. Sausville EA, LoRusso P, Carducci MA, Barker PN, Agbo F, Oakes P, Senderowicz AM. Phase I doseescalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors. J Clin Oncol 2011:29suppl; abstr 3058.
32. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007; 13:1955-60; PMID:17404075; http://dx.doi.org/10.1158/1078-0432.CCR-06-2793.
33. Guha M. PARP inhibitors stumble in breast cancer. Nat Biotechnol 2011; 29:373-4; PMID:21552220; http://dx.doi.org/10.1038/nbt0511-373.
34. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-34; PMID:19553641; http://dx.doi.org/10.1056/ NEJMoa0900212.
35. Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011; 104:750-5; PMID:21326243; http://dx.doi.org/10.1038/bjc.2011.8.
36. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235-44; PMID:20609467; http://dx.doi.org/10.1016/S0140-6736(10)60892- 6.
37. Riches LC, Lynch AM, Gooderham NJ. Early events in the mammalian response to DNA double-strand breaks. Mutagenesis 2008; 23:331-9; PMID:18644834; http://dx.doi.org/10.1093/mutage/gen039.
38. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Ann rev Biochem 2004; 73:39-85; http://dx.doi.org/10.1146/annurev. biochem.73.011303.073723.
39. Ström CE, Johansson F, Uhlén M, Szigyarto CA, Erixon K, Helleday T. Poly(ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res 2011; 39:3166-75; PMID:21183466; http://dx.doi.org/10.1093/nar/gkq1241.
40. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003; 159:439-52; PMID:12643788; http://dx.doi.org/10.1667/0033-7587(2003) 159[0439:EGFAIR]2.0 .CO;2.
41. Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF, Valerie K. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res 2007; 67:1046-53; PMID:17283137; http://dx.doi.org/10.1158/0008-5472.CAN-06- 2371.